Oxygenta Pharmaceutical concluded its 33rd Annual General Meeting on August 21, 2026, with shareholders approving all seven resolutions placed before them. The meeting was held via video conferencing.

A total of 4,472,167 votes were polled out of 36,983,500 shares held by shareholders on the record date of August 14, 2026. This represents a turnout of approximately 12.09% of outstanding shares. The promoter group held 20,909,870 shares but did not cast any votes during the remote e-voting or the meeting.

Voting Results Overview

The voting process was scrutinized by M/s. Aakanksha Dubey & Co. Participation included 75 members via video conferencing (73 public, 2 promoters) and remote e-voting. Notably, public non-institutional shareholders accounted for all votes cast, with a participation rate of 27.84% among that category.

Key Approvals

Shareholders approved two ordinary resolutions concerning material related-party transactions with the holding company, Virupaksha Organics Limited. These covered sales and purchase agreements, as well as loan and guarantee facilities. While these resolutions passed comfortably, they received slightly higher dissent than other agenda items, with 109 votes cast against the loan and guarantee resolution compared to just one vote against most other items.

The Board also ratified the remuneration for the cost auditor for the financial year 2026-27. All directors and key managerial personnel, including CFO Mr. Prasad Reddy Battinapatla and Company Secretary Ms. Kumkum Bajaj, attended the meeting to address member queries regarding financials and future outlook.

Oxygenta Pharmaceutical Limited has announced the book closure dates for its 33rd Annual General Meeting (AGM), which will impact trading in its equity shares on the Bombay Stock Exchange (BSE). The Register of Members and share transfer books will remain closed from August 15, 2026, to August 21, 2026, both days inclusive. This closure is necessary to ascertain the list of shareholders entitled to attend and vote at the meeting, which is scheduled to be held on August 21, 2026, at 10:30 a.m. through Video Conference or Other Audio-Visual Means.

The company notified the BSE of these dates on July 30, 2026, via a submission signed by Executive Director Balasubba Reddy Mamilla. The notice confirms that the meeting will address the businesses transacted during the financial year, with shareholders holding securities either in physical form or in dematerialized form eligible to participate.

Key Dates for Shareholders

Shareholders must note specific deadlines to ensure their voting rights are recognized. The company has fixed Friday, August 14, 2026, as the cut-off date for remote e-voting. This date determines which shareholders are entitled to cast their votes electronically before the physical/virtual meeting takes place.

Regulatory Compliance

The announcement aligns with standard regulatory requirements for public listed entities in India. By closing the books, Oxygenta Pharmaceutical ensures a static shareholder register for the duration of the voting process, preventing changes in ownership that could complicate vote counting. The use of remote e-voting allows shareholders who cannot attend the virtual meeting in real-time to exercise their franchise up to the specified cut-off date.

What This Means for Investors

For investors holding equity shares of Oxygenta Pharmaceutical Limited (ISIN: INE102E01018), the primary implication is a temporary suspension of trading activity from August 15 to August 21, 2026. During this period, shares cannot be bought or sold on the BSE. Investors wishing to participate in the corporate governance process must ensure they hold shares as of the record date determined by the book closure. Those intending to vote remotely must do so by August 14, 2026, to have their votes counted for the resolutions presented at the 33rd AGM.